Terapia Customizzata delle Disfunzioni Lacrimali

Maurizio Rolando

Genova

Who is my patient with Tear Dysfunction?

- the "aggressive environment prisoner"
 - (sick building, traveler, etc.)
- ▶ the computer user
- the patient with chronic allergy
- the peri-menopausal lady
- the patient with rheumatic disease
- the patient with systemic therapy
- the patient with blepharitis
- the contact lens wearer
- the refractive surgery patient
- the patient who had cataract or ocular surface surgery
- the patient in anti-galucoma topical therapy







The ocular surface system

- tear film
- corneal epithelium
- ► limbal epithelium
- conjunctival epithelium
- conjunctival goblet cells
- muco-epidermal junction
- lacrimal glands
- lacrimal sac and tear outflow system

(tear fluid, hormones, blood, nerves, cytokines...)





Prolonged Environmental "Stress" Decreases Tear Secretion in Otherwise Normal Mice






Controlled Environment Chamber

• Temperature: 22.3 ± 0.7 °C


• Relative Humidity: $18.5\% \pm 4.5\%$

• Air flow: 15 l/min


Tear Secretion



* p<0.005 vs control § p=0.001 vs baseline



p<0.0001 vs control and baseline



* p<0.005 vs control° p<0.05 vs baseline




- Cotton threads embedded with phenol red
- Remove excessive tears (3")
- Test: 30"

Risk Factors Associated With Dry Eye

Level of Evidence					
Mostly consistent	Suggestive	Unclear			
 Older age Female gender Postmenopausal estrogen therapy Low dietary intake of omega -3 fatty acids Medications Antihistamines Connective tissue disease LASI K and refractive excimer laser surgery Radiation therapy Hematopoietic stem cell transplantation Vitamin A deficiency Hepatitis C infection Androgen deficiency 	 Asian ethnicity Medications Tricyclic antidepressants Selective serotonin reuptake inhi bitors Diuretics Beta -blockers Diabetes mellitus HIV/HTLV1 infection Systemic chemotherapy Large -incision ECCE and penetrating keratoplasty Isotretinoin Low -humidity environments Sarcoidosis Ovarian dysfunction 	Cigarette smoking Hispanic ethnic ity Medications Anticholinergics Anxiolytics Antipsychotics Alcohol use Menopause Menopause Botulinum toxin injection Acne Gout Oral contraceptives Pregnancy Ational Dry Eye WorkShop (2007). Ocul Surf. 200			


Pragmatic, Treatment Oriented, Clinical Classification of Dry Eye



The Delphi Panel on Dry Eye Baltimore, November 2003

Delayed Tear Clearance


Depletion of
OS Protective Factors
Accumulation of Toxic /
Inflammatory Factors




THE TOXIC TEARS


- Pro inflammatory tears become toxic to the ocular surface epithelium
- The concept of "toxic tears" could help explain many of the symptoms reported by patients in the earliest phases of the disease—when almost no sign is present of ocular surface damage.







Tear Dysfunction Cascade





Progression of Dry Eye Severity Levels

LEVEL 1	Mild to moderate symptoms, no visual signs Mild to moderate conjunctival signs
LEVEL 2	Moderate to severe symptoms Tear film signs, visual signs Mild corneal punctate staining Conjunctival staining
LEVEL 3	Severe symptoms Marked corneal punctate staining Central corneal staining Filamentary keratitis
LEVEL 4	Severe symptoms Severe corneal staining, erosions Conjunctival scarring

Behrens et al. Cornea. 2006;25:900-907.

Aim of Dry Eye Therapy

- Re-build the O.S. System homeostasis by addressing:
 - Tear toxicity (remove / correct / prevent cytotoxic agents, proinflammatory agents, etc.)
 - Tear volume (secretagogues, tear substitutes)
 - Tear stability (mild tensio active agents, lipid integration)
 - Tear turnover (secretagogues, tear substitutes)
 - Tear distribution (correct lids, correct blinking habits)
- Improve symptoms (palliative)
 - Improve quality of life (tear substitutes, fatty acids)
 - Improve quality of vision (lipid containing / long lasting stabilizing tear substitutes)

Chronic O.S. Diseases Therapy

- Dynamic
 - Set the target, obtain the result then change
 - Maximum effect low toxicity
- Multiple
 - Tear volume
 - Tear turnover
 - Epithelial healing/protection
 - Inflammation
 - Lid conditions
- Simultaneous
 - Addressing all the concurrent conditions at the same time, if possible
- Topical and systemic

Treat All Conditions Together Break the Vicious Cycles

- increase tear volume
 - systemic pilocarpine
 - volumetric tear substitutes
 - punctum plugs
- Improve lubrication
 - Non Newtonian tear substitutes
- dilute tear film solutes
 - Increase tear turnover
- improve mucus conditions
 - gefarnate, Ecabet, N-Acetyl Cisteine,
 TSP, P2Y (?), 15-(S)-HETE.,
 Rebopamide
- improve corneal epithelium
 - semi compressive eye patching
 - contact lenses
 - amniotic membrane
- reduce evaporation
 - lipid tears (?)
 - lateral tarsorraphy
 - life style adaptation

- treat the lids
 - Warm patches
 - Antibiotics
 - Steroids and combo
 - Omega 3-6 ointments
 - Blink exercises
 - loose & floppy eye lid correction
- control inflammation
 - steroids,
 - NSAIDs
 - Cyclosporine A
 - Omega 3-6 Fatty Acids
 - Androgens
 - Tetracyclin & Derivatives
- supplement growth factors
 - autoserum eye drops
 - amniotic membrane
 - NGF

Overcome Steroid Toxicity

- Dry eye is a chronic disease that requires chronic therapy
- Toxicity of corticosteroids potentially limits their longterm use
 - Ocular hypertension and glaucoma
 - Posterior subcapsular cataracts
 - Infection


- Look for potentially safe topical steroids [(very)Low doses, poor penetration formulations, target activated, rapidly inactivated, no active metabolite, etc...]
- Use pulsed or tapered therapy



Steroid Toxicity


- Dry eye is a chronic disease that requires chronic therapy
- Toxicity of corticosteroids potentially limits their longterm use
 - Ocular hypertension and glaucoma
 - Posterior subcapsular cataracts
 - Infection
- Look for potentially safe steroids (loteprednol etabonate, rimexolon, etc...)
- Use pulsed or tapered therapy





Steroid Dosing for KCS Therapy

□ number of drops





Dry Eye Treatment Chart

Severity Level	1	2	3	4
Symptoms	Mild to moderate	Moderate to severe	Severe	Severe
Conjunctival signs	Mild to moderate	Staining	Staining	Scarring
Corneal staining		Mild punctate staining	Marked punctate staining; central staining; filamentary keratitis	Severe staining; corneal erosions
Other signs		Tear film; vision (blurring)		

Treatment Options

- Patient education
- Environmental modification
- Preserved tears (?)
- Unpreserved tears
- Gels, ointments
- · Topical steroids, cyclosporine A
- Secretagogues
- Nutritional support

- Oral tetracyclines
- Punctal plugs (once inflammation is controlled)
- Autologous serum

- Systemic antiinflammatory therapy
- Oral cyclosporine A
- Acetylcysteine
- Moisture goggles
- Surgery (punctal cautery)

If no improvement, add level 2 treatments



If no improvement, add level 4 treatments

Meibomian gland disease—treatment options Lid hygiene; thermomassage; oral tetracyclines

Level 1 Treatment Options

Level 1 is characterized by mild to moderate symptoms and conjunctival staining

- Patient education
 - Improve habits during computer use, reading
- Environmental modification
 - Avoid desiccating environments
 - Use humidifier
- Preserved tears*
- Control allergy or lid changes

* If used more than QID better unpreserved

Level 2 Treatment Options

Level 2 is characterized by moderate to severe symptoms and mild corneal punctate staining

- Unpreserved tears
- Gels, ointments
- Topical anti-inflammatory therapies
 - Topical steroids
 - Useful but potential side effects, look for safe molecules
 - Cyclosporine 0.05% ophthalmic emulsion
 - Topic Omega 3
- Secretagogues
- Nutritional support
 - Fatty acid supplements (omega 3)

Level 3 Treatment Options

Level 3 is characterized by severe symptoms and marked corneal punctate staining


- Oral tetracyclines
- Punctal plugs
 - May increase comfort and reduce the use of supplemental lubrication¹
 - Plugs may increase damage to the ocular surface if inflammation is not controlled first²
- Autologous serum

- 1. Balaram et al. *Am J Ophthalmol*. 2001;131:30-36;
- Behrens et al. Cornea. 2006;25:900-907.

Level 4 Treatment Options

Level 4 consists of severe symptoms, conjunctival scarring, and severe corneal staining

- Systemic anti-inflammatory therapy
- Oral cyclosporine A (?)
- (Acetylcysteine)
- Moisture goggles
- Surgery (punctal cautery, etc.)





Think Tear Dysfunction in the Ocular Surface System!

- assess your (prevalent) diagnosis
 - local and systemic
- Always consider the "functional unit" theory
 - lids
 - epithelial cells
 - mucins
 - cornea sensation
 - tear turnover and volume

- treat all conditions together
 - break the vicious cycles
- be dynamic
 - Adapt your therapy to the conditions as they change
- avoid toxicity
 - too much is too much
- explain the disease and the treatment
- teach prevention
- support the patient